Dilution of Share Value from Stock Options
First written in FY2019. 4 of 16 entries say "Mitigated", first in FY2020. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026MitigatedAnnual report
「As of the end of the consolidated fiscal year, the total number of potential shares from stock options was 34,000, equivalent to 1.30% of the 2,608,600 shares issued and outstanding.」
Following the completion of the exercise of 207,000 shares under the Seventh Series Stock Acquisition Rights and other factors, the percentage of potential shares declined from 6.00% in the previous fiscal year to 1.30%. - FY2026-H1MaterialisedAnnual report
「1 April 2025–30 September 2025 207,000 2,606,600 70,383 386,267 70,383 376,267 (Note) The increase resulted from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights added 207,000 shares to the shares issued and outstanding, converting dilution risk into actual share issuance. - FY2025Issue and partial exercise of the Seventh Series Stock Acquisition RightsAnnual report
「Increase from the issue of the Seventh Series Stock Acquisition Rights 250,000 shares Decrease from the exercise of the Seventh Series Stock Acquisition Rights 43,000 shares」
The Seventh Series Stock Acquisition Rights left the equivalent of 207,000 common shares outstanding at the end of the period. The percentage of potential shares represented by all stock options declined from 6.12% in the previous fiscal year to 6.00%. - FY2024WorsenedAnnual report
「As of the end of the consolidated fiscal year, the total number of potential shares from stock options was 144,000, equivalent to 6.12% of the 2,352,600 shares issued and outstanding.」
The percentage of potential shares rose from 2.25% in the previous fiscal year to 6.12%. The addition of 70,000 shares under the Fifth Series and 21,000 shares under the Sixth Series Stock Acquisition Rights increased the dilution exposure. - FY2024-Q3RestatedAnnual report
「Overview of potential shares that were excluded from the calculation of diluted quarterly net income per share because they had no dilutive effect, but had undergone material changes since the end of the previous consolidated fiscal year — Issue of the Fifth Series Stock Acquisition Rights Stock options granted pursuant to a resolution of the Board of Directors dated 27 June 2023 (stock acquisition rights) (Number of shares: 70,000)」
The disclosure of potential shares comprising 70,000 common shares related to the Fifth Series Stock Acquisition Rights has been repeated. - FY2024-Q2Update to the terms of issue of stock acquisition rightsAnnual report
「Sixth Series Stock Acquisition Rights Resolution date 14 August 2023 Eligible recipients and number of recipients (people) Company employees 7 Class, description and number of shares underlying the stock acquisition rights (shares) ※ Common shares 21,000 (Notes 1 and 2)」
The terms of issue of the Sixth Series Stock Acquisition Rights are disclosed as covering 21,000 common shares for 7 employees. - FY2024-Q1WorsenedAnnual report
「Based on a resolution of the Board of Directors meeting held on 27 June 2023, the Company issued the stock acquisition rights described below as stock options to 1 director and 1 employee, which were allotted on 14 July 2023.」
Stock options covering 70,000 common shares were allotted as the Fifth Series Stock Acquisition Rights. The disclosure also records a resolution to issue the Sixth Series Stock Acquisition Rights to 7 employees, covering 21,000 common shares, providing additional information on potential shares. - FY2023MitigatedAnnual report
「As of the end of the consolidated fiscal year, the total number of potential shares from stock options was 53,000, equivalent to 2.25% of the 2,352,600 shares issued and outstanding.」
The percentage of potential shares declined from 5.09% in the previous fiscal year to 2.25%, reflecting the waiver of rights to 50,000 shares under the Fourth Series Stock Acquisition Rights and the exercise of existing stock acquisition rights. - FY2023-Q1Increase in shares issued and outstanding through the exercise of stock acquisition rightsAnnual report
「1 April 2022–30 June 2022 (Note) The increase resulted from the exercise of stock acquisition rights. 16,000 2,352,600 3,798 295,722 3,798 285,722」
The exercise of stock acquisition rights increased the share count by 16,000, and the figures for shares issued and outstanding, stated capital and capital surplus were updated. - FY2022MitigatedAnnual report
「As of the end of the consolidated fiscal year, the total number of potential shares from stock options was 119,000, equivalent to 5.09% of the 2,336,600 shares issued and outstanding.」
The percentage of potential shares declined from 5.20% previously to 5.09%, while information on potential shares, including those related to the Fourth Series Stock Acquisition Rights, was updated. - FY2022-Q3Update of potential share informationAnnual report
「Overview of potential shares that were not included in the calculation of quarterly net income per share after dilution because they had no dilutive effect and that underwent significant changes from the end of the previous consolidated fiscal year Stock options based on a resolution of the Board of Directors held on 23 July 2018 Number of stock acquisition rights 280 Common shares 28,000 Issuance of the fourth series of stock acquisition rights Stock options granted pursuant to a resolution of the Board of Directors dated 29 June 2021 (Stock acquisition rights) (Number of shares: 50,000 shares)」
The note on diluted earnings per share has been updated to include information on the existing 28,000 shares and 50,000 shares related to the Fourth Series Stock Acquisition Rights. - FY2022-Q1WorsenedAnnual report
「29 June 2021 Director of the Company 1 Number of stock acquisition rights 500 Common shares 50,000 Exercise period for stock acquisition rights 16 July 2024 to 30 June 2031」
The Company resolved to issue the fourth series of stock acquisition rights, with 50,000 common shares as the underlying shares, to 1 director, adding the potential share information. - FY2021-Q3Update of potential share informationAnnual report
「Overview of potential shares that were not included in the calculation of quarterly net income per share after dilution because they had no dilutive effect and that underwent significant changes from the end of the previous fiscal year Stock options based on a resolution of the Board of Directors held on 23 July 2018 Number of stock acquisition rights 280 Common shares 28,000」
The note on diluted earnings per share identifies the 28,000 shares under the stock options resolved in 2018 as information involving a significant change. - FY2021-Q2New issuance resolved after the exercise of existing stock acquisition rightsAnnual report
「21 July 2020 (Note) The increase resulted from the exercise of stock acquisition rights. / At a meeting of the Board of Directors held on 13 November 2020, the Company resolved to issue stock acquisition rights to its employees as stock options on the following terms. / Common shares 20,000」
While 4,000 shares increased through the exercise of stock acquisition rights in July 2020, the Company subsequently resolved to issue stock acquisition rights for 20,000 shares to 2 employees. The reduction in existing rights and the new grant are presented together. - FY2020MitigatedAnnual report
「As of the date of submission of this document, the total number of potential shares under stock options was 121,000, equivalent to 5.20% of the total 2,328,600 issued shares.」
The total number of potential shares and their percentage of total issued shares decreased from the previously reported 130,000 shares and 5.58% to 121,000 shares and 5.20%. - FY2019First statedAnnual report
「As of the date of submission of this document, the total number of potential shares under stock options was 130,000, equivalent to 5.58% of the total 2,328,600 issued shares.」
The Company discloses the dilution risk upon exercise while granting stock acquisition rights as an incentive to secure human resources.